Rib-X's skin infection drug enters late-stage study

05/17/2013 | Pharmaceutical Business Review Online

Rib-X Pharmaceuticals initiated a late-stage trial to assess the efficacy of a Captisol-enabled IV formulation of delafloxacin in patients with acute bacterial skin and skin structure infections. The trial triggered the payment of a $500,000 milestone fee to partner Ligand Pharmaceuticals.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC